Methodological quality in pharmacogenetic studies with binary assessment of treatment response: A review

Pharmacogenetics and Genomics

Volumn 21, Issue 5, 2011, Pages 243-250

  Cobos, Albert ^a   Sánchez, Pilar ^a   Aguado, Jaume ^a   Carrasco, Josep Lluís ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

genetic association studies; Hardy Weinberg equilibrium; multiplicity; pharmacogenetics; single nucleotide polymorphism; statistical analysis

Indexed keywords

ARTICLE; GENE FREQUENCY; GENOTYPE; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; PHARMACOGENETICS; RESEARCH DESIGN; RESEARCH REPORT; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 79955419677     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834300fb     Document Type: Article

References (59)

1. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 29:306-309. (Pubitemid 33096456)
2. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865-872. (Pubitemid 36331853)
3. Ryan SG. Regression to the truth: replication of association in pharmacogenetic studies. Pharmacogenomics 2003; 4:201-207. (Pubitemid 36336459)
4. Lalouel JM, Rohrwasser A. Power and replication in case-control studies. Am J Hypertens 2002; 15:201-205. (Pubitemid 34161099)
5. Adetugbo K,Williams H. How well are randomized controlled trials reported in the dermatology literature? Arch Dermatol 2000; 136:381-385. (Pubitemid 30149113)
6. DerSimonian R, Charette LJ, McPeek B, Mosteller F. Reporting on methods in clinical trials. N Engl J Med 1982; 306:1332-1337. (Pubitemid 12105160)
7. Kjaergard LL, Nikolova D, Gluud C. Randomized clinical trials in HEPATOLOGY: predictors of quality. Hepatology 1999; 30:1134-1138. (Pubitemid 29510849)
8. Moher D, Dulberg CS, Wells GA. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 1994; 272:122-124. (Pubitemid 24206043)
9. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996; 276:637-639. (Pubitemid 26278070)
10. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010; 152:726-732.
11. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al.; Consolidated Standards of Reporting Trials Group. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010; 63:e1-e37.
12. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001; 357:1191-1194. (Pubitemid 32378696)
13. Egger M, Juni P, Bartlett C. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001; 285:1996-1999. (Pubitemid 32366953)
14. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001; 285:1992-1995. (Pubitemid 32366952)
15. Ioannidis JP, Gwinn M, Little J, Higgins JP, Bernstein JL, Boffetta P, et al. A road map for efficient and reliable human genome epidemiology. Nat Genet 2006; 38:3-5. (Pubitemid 43011872)
16. Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH. A review on the design and reporting of studies on drug-gene interaction. J Clin Epidemiol 2005; 58:651-654. (Pubitemid 40797893)
17. Attia J, Thakkinstian A, D'Este C. Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J Clin Epidemiol 2003; 56:297-303. (Pubitemid 36593307)
18. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361:567-671.
19. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33:177-182. (Pubitemid 36177070)
20. Little J, Higgins PT, Ioannidis J, Moher D, Gagnon F, Elm E, et al. Strengthening the Reporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. Genet Epidemiol 2009; 33:581-598.
21. Jorgensen AL, Williamson P. Methodological quality of pharmacogenetic studies: Issues of concern. Stat Med 2008; 27:6547-6569.
22. Donahue MP, Kraus WE. Genetic associations studies; the good, the bad, and the ugly. Am Heart J 2007; 154:610-612.
23. Ring HZ, Kroetz DL. Candidate gene approach for pharmacogenetic studies. Pharmacogenomics 2002; 3:47-56. (Pubitemid 34285238)
24. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147:W163-W194. (Pubitemid 351664503)
25. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007; 85:867-872. (Pubitemid 350086459)
26. Freidlin B, Zheng G, Li Z, Gastwirth JL. Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002; 53:146-152.
27. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7:781-791. (Pubitemid 44413222)
28. Sasieni PD. From genotypes to genes: doubling the sample size. Biometrics 1997; 53:1253-1261. (Pubitemid 28013569)
29. Attia J, Ioannidis JPA, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, et al. How to use an article about genetic association b: are the results of the study valid? JAMA 2009; 301:191-197.
30. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epid 2001; 54:979-985. (Pubitemid 32888364)
31. Tetrault JM, Sauler M, Wells CK, Concato J. Reporting of multivariable methods in the medical literature. J Investig Med 2008; 56:954-957.
32. Hunter DJ, Kraft P. Drinking from the fire hose: statistical issues in genomewide association studies. N Engl J Med 2007; 357:436-439. (Pubitemid 47204871)
33. Hattersley AT, McCarthy MI.What makes a good genetic association study? Lancet 2005; 366:1315-1323. (Pubitemid 41416588)
34. McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 2000; 18:505-508. (Pubitemid 30313953)
35. Slager SL, Schaid DJ. Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. Hum Hered 2001; 52:149-153. (Pubitemid 34701500)
36. Bromley C, Close S, Cohen N, Favis R, Fijal B, Gheyas F, et al. Designing pharmacogenetic project in industry: practical design perspectives from the Industry Pharmacogenomics Working Group. Pharmacogenomics J 2009; 9:14-22.
37. Perneger TV. What's wrong with Bonferroni adjustments? BMJ 1998; 316:1236-1238.
38. Rosenberg PS, Che A, Chen BE. Multiple hypothesis testing strategies for genetic case-control association studies. Stat Med 2006; 25:3134-3149. (Pubitemid 44377336)
39. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96:434-442. (Pubitemid 38443646)
40. Ohashi J, Yamamoto S, Tsuchiya N, Hatta Y, Komata T, Matsushita M, et al. Comparison of statistical power between 2*2 allele frequency and allele positivity tables in case-control studies of complex disease genes. Ann Hum Genet 2001; 65:197-206. (Pubitemid 32452121)
41. Xu J, Wacholder S. Positive results in association studies are associated with departure from Hardy-Weinberg equilibrium: hint for genotyping error? Hum Genet 2002; 111:573-574. (Pubitemid 36075091)
42. Salanti G, Amountza G, Ntzani EE, Ioannidis JP. Hardy-Weinberg equilibrium in genetic association studies: an empirical evaluation of reporting, deviations, and power. Eur J Hum Genet 2005; 13:840-848. (Pubitemid 40946083)
43. Schor S, Karten I. Statistical evaluation of medical journal manuscripts. JAMA 1966; 195:1123-1128.
44. Gore SM, Jones IG, Rytter EC. Misuse of statistical methods: critical assessment of articles in BMJ from January to March 1976. Br Med J 1977; 1:85-87. (Pubitemid 8017514)
45. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials: a survey of three medical journals. N Engl J Med 1987; 317:426-432. (Pubitemid 17131180)
46. Gardner MJ, Bond J. An exploratory study of statistical assessment of papers published in the British Medical Journal. JAMA 1990; 263: 1355-1357. (Pubitemid 20069941)
47. Garcia-Berthou E, Alcaraz C. Incongruence between test statistics and P values in medical papers. BMC Med Res Methodol 2004; 4:13.
48. Strasak A, Zaman Q, Marinell G, Pfeiffer P, Ulmer H. The use of statistics in medical research: a comparison of The New England Journal of Medicine and Nature Medicine. Am Stat 2007; 61:47-55.
49. Weiss ST, Silverman EK, Palmer LJ. Case-control association studies in pharmacogenetics. Pharmacogenomics J 2001; 1:157-158.
50. Martin L, Woo J, Avery C, Chen H-S, North KE; on behalf of Group 15. Multiple testing in the genomics era: findings from Genetic Analysis Workshop 15, Group 15. Genet Epidemiol 2007; 31: S124-S131.
51. Gauderman W, Morrison J: QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies Available from: http://hydra.usc.edu/gxe. Accessed January 14th 2011.
52. Cordell HJ, Clayton DG. Genetic association studies. Lancet 2005; 366:1121-1131. (Pubitemid 41338767)
53. Burton PR, Tobin MD, Hopper JL. Key concepts in genetic epidemiology. Lancet 2005; 366:941-951. (Pubitemid 41265670)
54. Little J, Bradley L, Bray MS, Clyne M, Dorman J, Ellsworth DL, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002; 156:300-310. (Pubitemid 34857997)
55. Daly AK, Day CP. Candidate gene case-control association studies: advantages and potential pitfalls. Br J Clin Pharmacol 2001; 52:489-499.
56. Becker N, Nieters A, Rittgen W. Single nucleotide polymorphism, disease relationships: statistical issues for the performance of association studies. Mutat Res 2003; 525:11-18. (Pubitemid 36332254)
57. Meisel C, Gerloff T, Kirchheiner J, Mrozikiewicz PM, Niewinski P, Brockmoller J, et al. Implications of pharmacogenetics for individualizing drug treatment and for study design. J Mol Med 2003; 81:154-167. (Pubitemid 36470182)
58. Need AC, Motulsky AG, Goldstein DB. Priorities and standards in pharmacogenetic research. Nat Genet 2005; 37:671-681. (Pubitemid 41754883)
59. Altman DG, Hoey J, Moher D, Schulz KF. Equator network. 2008. http:// www.equator-network.org/. (Accessed 12 August 2008).